Noxopharm Ltd - Asset Resilience Ratio

Latest as of December 2025: 1.92%

Noxopharm Ltd (NOX) has an Asset Resilience Ratio of 1.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Noxopharm Ltd (NOX) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$91.40K

≈ $64.67K USD Cash + Short-term Investments

Total Assets

AU$4.75 Million

≈ $3.36 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how Noxopharm Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Noxopharm Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Noxopharm Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Noxopharm Ltd (NOX) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$91.40K	1.92%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$91.40K	1.92%

Asset Resilience Insights

Limited Liquidity: Noxopharm Ltd maintains only 1.92% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Noxopharm Ltd Industry Peers by Asset Resilience Ratio

Compare Noxopharm Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Noxopharm Ltd (2016–2023)

The table below shows the annual Asset Resilience Ratio data for Noxopharm Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-06-30	0.00%	AU$0.00 ≈ $0.00	AU$10.13 Million ≈ $7.17 Million	--
2022-06-30	30.08%	AU$8.00 Million ≈ $5.66 Million	AU$26.59 Million ≈ $18.82 Million	+9.19pp
2021-06-30	20.90%	AU$10.00 Million ≈ $7.08 Million	AU$47.85 Million ≈ $33.86 Million	-46.76pp
2019-06-30	67.66%	AU$2.91 Million ≈ $2.06 Million	AU$4.30 Million ≈ $3.04 Million	-19.04pp
2018-06-30	86.69%	AU$12.61 Million ≈ $8.92 Million	AU$14.55 Million ≈ $10.29 Million	-0.20pp
2017-06-30	86.89%	AU$2.46 Million ≈ $1.74 Million	AU$2.83 Million ≈ $2.00 Million	+86.74pp
2016-06-30	0.15%	AU$9.56K ≈ $6.76K	AU$6.21 Million ≈ $4.39 Million	--

pp = percentage points

About Noxopharm Ltd

AU:NOX Australia Biotechnology

Market Cap

$13.26 Million

AU$18.74 Million AUD

Market Cap Rank

#26431 Global

#1202 in Australia

Share Price

AU$0.06

Change (1 day)

-1.61%

52-Week Range

AU$0.06 - AU$0.11

All Time High

AU$1.58